Huasun plans to publicly list and transfer 51% equity of Tibet Kangyu

Zhitong
2025.08.01 12:43
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Huasun announced that the company plans to publicly transfer 51% of the equity of its controlling subsidiary Tibet Kangyu Pharmaceutical Co., Ltd. (referred to as "Tibet Kangyu") at a listing price of 63.7806 million yuan. The equity transfer will be conducted through public listing at the Southwest United Property Rights Exchange, and the buyer has not yet been determined

According to the announcement from Zhitong Finance APP, Huasun Technology (000790.SZ) plans to publicly transfer 51% equity of its controlling subsidiary Tibet Kangyu Pharmaceutical Co., Ltd. (referred to as "Tibet Kangyu") at a listing price of 63.7806 million yuan. This equity transfer will be conducted through public listing at the Southwest United Property Rights Exchange, and the transaction assignee has not yet been determined

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer